menu
    • menu
    [{"orgOrder":0,"company":"Neon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NEO-PTC-01","moa":"Neoantigen-targeting T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Neon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Neon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neon Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Acquisition","leadProduct":"NEO-STC-01","moa":"RAS neoantigen","graph1":"Oncology","graph2":"Preclinical","graph3":"Neon Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Neon Therapeutics \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Neon Therapeutics \/ BioNTech"}]

    Find Clinical Drug Pipeline Developments & Deals by Neon Therapeutics

    Menu

    Neon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neon Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neon Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEO-PTC-01

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01

                            Details : Neon’s initial Phase 1 clinical trial of NEO-PTC-01 will be conducted in patients with metastatic melanoma who are not responsive to checkpoint inhibitors.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 30, 2020

                            Lead Product(s) : NEO-PTC-01

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neon Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neon Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEO-STC-01

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : BioNTech

                            Deal Size : $67.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            BioNTech to acquire Neon to strengthen global leadership position in T cell therapies

                            Details : This acquisition to expand BioNTech's capabilities and strengthens its immunotherapy pipeline.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $67.0 million

                            January 16, 2020

                            Lead Product(s) : NEO-STC-01

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : BioNTech

                            Deal Size : $67.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth